Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 1/20 | 0.72 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.53 |
| ▸ | AURKA | O14965 | 1/20 | 0.50 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.50 |
| ▸ | CDK2 | P24941 | 1/20 | 0.50 |
| ▸ | COMT | P21964 | 1/20 | 0.46 |
| ▸ | APEX1 | P27695 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | NSD2 | O96028 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | IDE | P14735 | 1/20 | 0.45 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.45 |
| ▸ | CCR6 | P51684 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | ATIC | P31939 | 2/20 | 0.44 |
| ▸ | ALPL | P05186 | 1/20 | 0.44 |
| ▸ | ALPI | P09923 | 1/20 | 0.44 |
| ▸ | ALPG | P10696 | 1/20 | 0.44 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30233642 | 0.97 | TTR (0.75) | TTRCYP1A2AURKAAURKBCDK2 | |
| SCHEMBL29363198 | 0.97 | TTR (0.75) | TTRCYP1A2AURKAAURKBCDK2 | |
| SCHEMBL6242 | 0.97 | TTR (0.75) | TTRCYP1A2AURKAAURKBCDK2 | |
| Water SCHEMBL242080 | 0.95 | TTR (0.72) | TTRCYP1A2AURKAAURKBCDK2 | |
| SCHEMBL2290618 | 0.95 | TTR (0.72) | TTRCYP1A2AURKAAURKBCDK2 | |
| Ammonia Solution, Strong SCHEMBL25312340 | 0.95 | TTR (0.72) | TTRCYP1A2AURKAAURKBCDK2 | |
| Ammonia Solution, Strong SCHEMBL10954121 | 0.95 | TTR (0.72) | TTRCYP1A2AURKAAURKBCDK2 | |
| Hydrochloric Acid SCHEMBL7455908 | 0.95 | TTR (0.72) | TTRCYP1A2AURKAAURKBCDK2 | |
| SCHEMBL8028660 | 0.95 | TTR (0.72) | TTRCYP1A2AURKAAURKBCDK2 | |
| Lithium SCHEMBL18420655 | 0.95 | TTR (0.72) | TTRCYP1A2AURKAAURKBCDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2614049-B1 | PLEUROMUTILIN DERIVATIVES FOR USE IN THE TREATMENT OF DISEASES MEDIATED BY MICROBES | Nabriva Therapeutics GmbH (AT) | 2018-02-28 | — | — | EP | disclosed |
| US-9278920-B2 | Pleuromutilin derivatives for use in the treatment of diseases mediated by microbes | NABRIVA THERAPEUTICS AG (AT) | 2016-03-08 | — | — | US | disclosed |
| US-20130274329-A1 | PLEUROMUTILIN DERIVATIVES FOR USE IN THE TREATMENT OF DISEASES MEDIATED BY MICROBES | NABRIVA THERAPEUTICS AG (AT) | 2013-10-17 | — | — | US | disclosed |
| EP-2614049-A1 | PLEUROMUTILIN DERIVATIVES FOR USE IN THE TREATMENT OF DISEASES MEDIATED BY MICROBES | Nabriva Therapeutics AG (AT) | 2013-07-17 | — | — | EP | disclosed |
| EP-2433926-A1 | Pleuromutilin derivatives for use in the treatment of diseases mediated by microbes | Nabriva Therapeutics AG (AT) | 2012-03-28 | — | — | EP | disclosed |
| WO-2012031307-A1 | PLEUROMUTILIN DERIVATIVES FOR USE IN THE TREATMENT OF DISEASES MEDIATED BY MICROBES | NABRIVA THERAPEUTICS AG (AT) | 2012-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274329-A1 | PLEUROMUTILIN DERIVATIVES FOR USE IN THE TREATMENT OF DISEASES MEDIATED BY MICROBES | Q6ZSR9, CUTA, MC4R | TTR 13/4885CYP1A2 1566/4885AURKA 1178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.